SCHEMBL2123631

SCHEMBL2123631

CCCCCCCCOc1ccc(-c2ccc(C=O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
HPGD P15428 3/20 0.61
LMNA P02545 1/20 0.61
MAPT P10636 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
RARB P10826 3/20 0.60
NR5A1 Q13285 1/20 0.54
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
TP53 P04637 1/20 0.53
TSHR P16473 1/20 0.53
PLA2G4B P0C869 1/20 0.51
CYP1A2 P05177 1/20 0.49
CYP19A1 P11511 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
LTA4H P09960 2/20 0.49
KDM4E B2RXH2 2/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7289971 1.00 ALDH1A1 (0.61) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL3071049 1.00 ALDH1A1 (0.61) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL3086009 1.00 ALDH1A1 (0.61) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL7288765 0.98 ALDH1A1 (0.63) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL13739981 0.98 ALDH1A1 (0.63) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL1864244 0.95 ALDH1A1 (0.67) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL10497693 0.95 ALDH1A1 (0.67) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL585375 0.95 ALDH1A1 (0.67) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL1164373 0.95 ALDH1A1 (0.67) ALDH1A1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL1164661 0.95 ALDH1A1 (0.67) ALDH1A1HPGDLMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220236-A1 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY 2003-11-27 US claimed
EP-0561639-A1 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 1993-09-22 EP claimed
EP-2586764-B1 COMPOUND HAVING BRANCHED ALKYL OR BRANCHED ALKENYL, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL ELEMENT JNC CORP (JP) 2019-09-18 EP disclosed
EP-2468740-B1 TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY DEVICES JNC CORP (JP) 2017-08-02 EP disclosed
US-20140178606-A1 CELLULOSE ACYLATE FILM, POLARIZER, AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2014-06-26 US disclosed
US-8477275-B2 Optical film and liquid crystal display device FUJIFILM CORPORATION (JP) 2013-07-02 US disclosed
US-20130128359-A1 OPTICAL FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY APPARATUS FUJIFILM CORPORATION (JP) 2013-05-23 US disclosed
US-8420187-B2 Cellulose acylate composition, cellulose acylate film, and its applications FUJIFILM CORPORATION (JP) 2013-04-16 US disclosed
US-20120092595-A1 Optical film, polarizing plate and liquid crystal display device FUJIFILM CORPORATION (JP) 2012-04-19 US disclosed
US-20120092594-A1 OPTICAL FILM AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2012-04-19 US disclosed
US-7790744-B2 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 2010-09-07 US disclosed
EP-0438754-A1 Optically active compound, intermediate therefor, process for producing the intermediate, and liquid-crystal composition DAINIPPON INK AND CHEMICALS, INC. (JP) 1991-07-31 EP disclosed
EP-0251335-B1 HALOGENEN-SUBSTITUTED PHENYL BENZYL ETHER DERIVATIVES, LIQUID CRYSTAL COMPOSITIONS CONTAINING THEM AND OPTICAL SWITCHING ELEMENT Chisso Corporation (JP) 1991-04-24 EP disclosed
EP-0290570-A1 CHIRAL OR ACHIRAL CYCLIC COMPOUNDS. MERCK PATENT GMBH (DE) 1988-11-17 EP disclosed
US-4784791-A LIQUID CRYSTAL COMPOUNDS FOR OPTICAL SWITCHES CHISSO CORPORATION (JP) 1988-11-15 US disclosed
EP-0174191-B1 LIQUID CRYSTAL COMPOUND HAVING METHYLENEOXY GROUP AND COMPOSITION CONTAINING SAME Chisso Corporation (JP) 1988-07-27 EP disclosed
US-4751019-A OPTICAL ACTIVITY CHISSO CORPORATION (JP) 1988-06-14 US disclosed
WO-1988003530-A1 CHIRAL OR ACHIRAL CYCLIC COMPOUNDS MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1988-05-19 WO disclosed
EP-0251335-A2 Halogenen-substituted phenyl benzyl ether derivatives, liquid crystal compositions containing them and optical switching element Chisso Corporation (JP) 1988-01-07 EP disclosed
US-4668427-A LIGHT SWITCHING ELEMENT CHISSO CORPORATION (JP) 1987-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220236-A1 Cyclic peptide antifungal agents and process for preparation thereof NGLY1, HM13, PTMS ALDH1A1 4721/4885HPGD 2068/4885LMNA 3429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.